Secretory Leukocyte Protease Inhibitor inhibits neutrophil apoptosis.
(2011) In Respirology Dec. p.300-307- Abstract
- SUMMARY AT A GLANCE: Secretory leukocyte proteinase inhibitor (SLPI) is a major anti-elastase barrier at the epithelial surfaces of upper respiratory tract. Our findings indicate clear up-regulation of SLPI in response to endotoxin in nasal secretions. In addition, SLPI shows dose-dependent anti-apoptotic and chemotactic effects on primary human neutrophils. ABSTRACT: Background and objective: The Secretory Leukocyte Protease Inhibitor (SLPI) is a major anti-elastase barrier at the epithelial surfaces of upper respiratory tract. In addition to its anti-protease activity, SLPI has been shown to express anti-bacterial, anti-viral and anti-inflammatory properties. Methods: We measured SLPI concentration in nasal lavage fluid of healthy... (More)
- SUMMARY AT A GLANCE: Secretory leukocyte proteinase inhibitor (SLPI) is a major anti-elastase barrier at the epithelial surfaces of upper respiratory tract. Our findings indicate clear up-regulation of SLPI in response to endotoxin in nasal secretions. In addition, SLPI shows dose-dependent anti-apoptotic and chemotactic effects on primary human neutrophils. ABSTRACT: Background and objective: The Secretory Leukocyte Protease Inhibitor (SLPI) is a major anti-elastase barrier at the epithelial surfaces of upper respiratory tract. In addition to its anti-protease activity, SLPI has been shown to express anti-bacterial, anti-viral and anti-inflammatory properties. Methods: We measured SLPI concentration in nasal lavage fluid of healthy volunteers after challenge with endotoxin (LPS) and evaluated SLPI effects in vitro on neutrophil chemotaxis, adhesion, cytokine (IL-8) release and apoptosis. Results: SLPI concentration in nasal lavage (n = 9) 2, 6 and 24 hrs after the challenge with LPS (25 µg) increased from 32% to 238% compared to baseline (226 ± 71 ng/ml). In vitro, SLPI (20 to 80µg/ml) induced neutrophil chemotaxis (6-fold, p < 0.001) and decreased neutrophil apoptosis by 73% (p = 0.006), relative to controls. However, SLPI had no affect on IL-8 release or neutrophil adhesion to fibronectin. SLPI-positive immunoreactivity was co-localised with neutrophils in lung specimens from patients with chronic obstructive pulmonary disease. Conclusions: Our findings indicate up-regulation of SLPI in response to LPS in nasal secretions and show anti-apoptotic effects of SLPI in primary human neutrophils suggesting a new role of SLPI during neutrophilic inflammation. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1731964
- author
- Subramaniyam, Devipriya ; Hollander, Camilla LU ; Westin, Ulla LU ; Erjefält, Jonas LU ; Stevens, Tim and Janciauskiene, Sabina LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Respirology
- volume
- Dec
- pages
- 300 - 307
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000286740700016
- pmid:21077989
- scopus:79551528410
- pmid:21077989
- ISSN
- 1440-1843
- DOI
- 10.1111/j.1440-1843.2010.01901.x
- language
- English
- LU publication?
- yes
- id
- dac14e7b-008c-4f94-9a40-8b00c9536495 (old id 1731964)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21077989?dopt=Abstract
- date added to LUP
- 2016-04-04 09:23:10
- date last changed
- 2022-01-29 17:38:29
@article{dac14e7b-008c-4f94-9a40-8b00c9536495, abstract = {{SUMMARY AT A GLANCE: Secretory leukocyte proteinase inhibitor (SLPI) is a major anti-elastase barrier at the epithelial surfaces of upper respiratory tract. Our findings indicate clear up-regulation of SLPI in response to endotoxin in nasal secretions. In addition, SLPI shows dose-dependent anti-apoptotic and chemotactic effects on primary human neutrophils. ABSTRACT: Background and objective: The Secretory Leukocyte Protease Inhibitor (SLPI) is a major anti-elastase barrier at the epithelial surfaces of upper respiratory tract. In addition to its anti-protease activity, SLPI has been shown to express anti-bacterial, anti-viral and anti-inflammatory properties. Methods: We measured SLPI concentration in nasal lavage fluid of healthy volunteers after challenge with endotoxin (LPS) and evaluated SLPI effects in vitro on neutrophil chemotaxis, adhesion, cytokine (IL-8) release and apoptosis. Results: SLPI concentration in nasal lavage (n = 9) 2, 6 and 24 hrs after the challenge with LPS (25 µg) increased from 32% to 238% compared to baseline (226 ± 71 ng/ml). In vitro, SLPI (20 to 80µg/ml) induced neutrophil chemotaxis (6-fold, p < 0.001) and decreased neutrophil apoptosis by 73% (p = 0.006), relative to controls. However, SLPI had no affect on IL-8 release or neutrophil adhesion to fibronectin. SLPI-positive immunoreactivity was co-localised with neutrophils in lung specimens from patients with chronic obstructive pulmonary disease. Conclusions: Our findings indicate up-regulation of SLPI in response to LPS in nasal secretions and show anti-apoptotic effects of SLPI in primary human neutrophils suggesting a new role of SLPI during neutrophilic inflammation.}}, author = {{Subramaniyam, Devipriya and Hollander, Camilla and Westin, Ulla and Erjefält, Jonas and Stevens, Tim and Janciauskiene, Sabina}}, issn = {{1440-1843}}, language = {{eng}}, pages = {{300--307}}, publisher = {{Wiley-Blackwell}}, series = {{Respirology}}, title = {{Secretory Leukocyte Protease Inhibitor inhibits neutrophil apoptosis.}}, url = {{http://dx.doi.org/10.1111/j.1440-1843.2010.01901.x}}, doi = {{10.1111/j.1440-1843.2010.01901.x}}, volume = {{Dec}}, year = {{2011}}, }